CPHI - Audit finds 'substantial doubt' about China Pharma's future; shares plummet 43%
An audit opinion issued by an independent accounting firm says that current liabilities and accumulated deficits have raised "substantial doubt" about China Pharma's (CPHI) ability to continue.The company's full-year 2020 results, released yesterday, showed GAP EPS of -$0.07 and total revenue of ~$10.9M.The company's bad debt expenses for 2020 was $115,186 compared to $3,153 in 2019.China Pharma shares plummeted 43.1% to $1.19 in after-hours trading on Friday.
For further details see:
Audit finds 'substantial doubt' about China Pharma's future; shares plummet 43%